Using the immune system to fight the deadly disease shows promise, executives say, but vaccines may take years to bring to market. Biotech executives and cancer researchers are excited about a resurgence in basic studies and clinical trials involving immunotherapeutic approaches to fighting the disease. They caution, however, that because cancer is so poorly understood, products in the marketplace may still be years away. FIGHTING THE GOOD FIGHT: A technician from Cytel, one of the many immun
Using the immune system to fight the deadly disease shows promise, executives say, but vaccines may take years to bring to market. |
 FIGHTING THE GOOD FIGHT: A technician from Cytel, one of the many immunotherapeutic biotech firms, works on developing a cancer vaccine. |
Dozens of biotech firms are researching and ...
Memory-enhancing neural networks may also drive involuntary musical loops in the brain.
View this Issue
In this webinar, Brian Hie will discuss Evo2, a state-of-the-art genomic foundation model capable of generalist prediction and design tasks across DNA, RNA, and proteins.
In this webinar, learn how scientists use advanced human brain models to uncover treatment strategies for complex neurological conditions.
Manufacturing cell-based therapeutics requires a robust workflow from start to finish.
Modern DNA synthesis platforms empower researchers to explore the molecular world, from next-generation sequencing to cell and gene therapy development.
This new product line is specifically engineered to meet the rigorous demands of immunology research, vaccine development, animal studies, cell and gene therapy, and therapeutic protein manufacturing.
New fluidics and clog detection systems further simplify operation and reduce instrument downtime
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies
Study identifies new metrics to enhance scRNA-seq based virtual cell modelling
